UCL spinout developing targeted AAV gene therapies for refractory focal epilepsy.
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Series A British EpilepsyGTx raised a $33 million Series A, with XGEN Venture and British Business Bank, to take the EPY201 gene therapy into phase 1/2a clinical trials. | $33M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.